Online citations, reference lists, and bibliographies.

Diagnosis And Management Of Paget's Disease Of Bone In Adults: A Clinical Guideline

S. Ralston, L. Corral-Gudino, C. Cooper, R. Francis, W. Fraser, L. Gennari, N. Guañabens, M. K. Javaid, R. Layfield, T. O'Neill, R. Russell, M. Stone, Keith Simpson, D. Wilkinson, R. Wills, M. Zillikens, S. P. Tuck
Published 2019 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
An evidence‐based clinical guideline for the diagnosis and management of Paget's disease of bone (PDB) was developed using GRADE methodology, by a Guideline Development Group (GDG) led by the Paget's Association (UK). A systematic review of diagnostic tests and pharmacological and nonpharmacological treatment options was conducted that sought to address several key questions of clinical relevance. Twelve recommendations and five conditional recommendations were made, but there was insufficient evidence to address eight of the questions posed. The following recommendations were identified as the most important: 1) Radionuclide bone scans, in addition to targeted radiographs, are recommended as a means of fully and accurately defining the extent of metabolically active disease in patients with PDB. 2) Serum total alkaline phosphatase (ALP) is recommended as a first‐line biochemical screening test in combination with liver function tests in screening for the presence of metabolically active PDB. 3) Bisphosphonates are recommended for the treatment of bone pain associated with PDB. Zoledronic acid is recommended as the bisphosphonate most likely to give a favorable pain response. 4) Treatment aimed at improving symptoms is recommended over a treat‐to‐target strategy aimed at normalizing total ALP in PDB. 5) Total hip or knee replacements are recommended for patients with PDB who develop osteoarthritis in whom medical treatment is inadequate. There is insufficient information to recommend one type of surgical approach over another. The guideline was endorsed by the European Calcified Tissues Society, the International Osteoporosis Foundation, the American Society of Bone and Mineral Research, the Bone Research Society (UK), and the British Geriatric Society. The GDG noted that there had been a lack of research on patient‐focused clinical outcomes in PDB and identified several areas where further research was needed. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
This paper references
10.1111/j.1445-5994.1977.tb03354.x
Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget's disease of bone.
T. Martin (1977)
Sarcoma arising in Paget's disease of the skull: case report.
A. Gandolfi (1979)
10.1097/00003086-198704000-00006
Skeletal distribution and biochemical parameters of Paget's disease.
P. Meunier (1987)
10.1002/art.1780400312
Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
L. Alvarez (1997)
10.1086/340731
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
N. Laurin (2002)
10.2106/00004623-198769050-00020
Total hip arthroplasty in Paget's disease. A follow-up note.
D. J. Mcdonald (1987)
Ultrastructural characteristics of osteoclasts in Paget's disease.
A. Rebel (1974)
[ published erratum appears in Bone 1996 Mar ; 18 ( 3 ) : 292 ]
JY Reginster (1995)
10.1212/WNL.29.4.448
Neurologic disturbances in Paget disease of bone
J. R. Chen (1979)
Paget's disease at the hip with osteoarthrosis: results of intertrochanteric osteotomy.
B. Roper (1971)
10.1136/bmj.1.5746.423
Effect of Actinomycin D on Paget's Disease of Bone
J. Fennelly (1971)
10.1016/J.BONE.2003.12.011
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
J. Walsh (2004)
10.1210/jc.80.2.595
A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone.
R. Bockman (1995)
: a review of 889 patients
TP vanStaa (1999)
10.1038/ng1332
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
G. Watts (2004)
10.2106/JBJS.CC.K.00170
Near Complete Necrosis of a Giant Cell Tumor After Treatment with Denosumab: A Case Report.
Elke R. Ahlmann (2012)
10.1056/NEJMcp1204713
Clinical practice. Paget's disease of bone.
S. Ralston (2013)
10.1016/0169-6009(92)90923-2
Canine distemper virus transcripts sequenced from pagetic bone.
M. Gordon (1992)
Paget’s disease of the hip
Javad Parvizi (2004)
10.1007/s00223-012-9652-z
Implications of a New Radiological Approach for the Assessment of Paget Disease
N. Guañabens (2012)
10.1038/nature11922
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.
H. J. Kim (2013)
10.2106/00004623-199173050-00013
Total knee arthroplasty for osteoarthrosis in patients who have Paget disease of bone at the knee.
G. Gabel (1991)
10.1136/bmj.i2016
GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction
P. Alonso-Coello (2016)
10.1359/JBMR.0403015
Novel UBA Domain Mutations of SQSTM1 in Paget's Disease of Bone: Genotype Phenotype Correlation, Functional Analysis, and Structural Consequences
L. Hocking (2004)
10.1007/s002560050456
Computed tomography of Paget disease of the skull versus fibrous dysplasia
J. Tehranzadeh (1998)
10.1007/BF00261784
A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget's disease
I. Fogelman (2004)
10.1016/S1470-2045(10)70010-3
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
D. Thomas (2010)
10.3892/ol.2017.5693
Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report
Takaaki Tanaka (2017)
10.1016/j.arth.2004.11.007
Total knee arthroplasty in patients with Paget's disease of bone at the knee.
Gwo-Chin Lee (2005)
10.1186/1748-5908-6-62
Application of GRADE: Making evidence-based recommendations about diagnostic tests in clinical practice guidelines
Jonathan H. Hsu (2011)
10.1007/s10067-008-1001-2
Vertebral “clover” scintigraphic image in a vertebral metastasis misdiagnosed with Paget’s disease
R. Reyes (2008)
marrow cultures from patients with Paget ’ s disease of bone
MA Birch (2000)
10.1172/JCI82012
Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.
J. Teramachi (2016)
10.1359/jbmr.070704
Comparison of Different Intravenous Bisphosphonate Regimens for Paget's Disease of Bone
D. Merlotti (2007)
10.1359/jbmr.061204
Delayed Development of Paget's Disease in Offspring Inheriting SQSTM1 Mutations
M. Bolland (2007)
10.1007/s00590-015-1659-5
Surgical treatment in spine Paget’s disease: a systematic review
Alberto Jorge-Mora (2015)
10.1210/jc.81.3.961
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
E. Siris (1996)
10.1007/s00223-017-0312-1
The Changing Presentation of Paget’s Disease of Bone in Australia, A High Prevalence Region
Cameron Britton (2017)
10.1302/0301-620X.63B4.6457839
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis?
D. Douglas (1981)
10.1302/0301-620X.53B4.660
PAGET'S DISEASE AT THE HIP WITH OSTEOARTHROSIS: RESULTS OF LNTERTROCHANTERIC OSTEOTOMY
B. Roper (1971)
10.1359/jbmr.1999.14.2.192
The Epidemiology of Paget's Disease in Britain: Is the Prevalence Decreasing?
Cyrus Cooper (1999)
10.1002/JBMR.5650090103
Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bon
M. Birch (1994)
10.1007/s00223-016-0150-6
Treatment of Paget’s Disease of Bone with Denosumab: Case Report and Literature Review
I. Reid (2016)
10.1016/S8756-3282(02)00817-7
Guidelines on the management of Paget's disease of bone.
P. Selby (2002)
10.1016/j.bone.2008.11.002
Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation.
D. Mangham (2009)
10.1097/00003086-198403000-00044
Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone.
B. Mills (1984)
10.1385/BMM:1:2:099
Epidemiology of Paget's disease of bone
R. Altman (2002)
10.1016/S0002-9343(99)00062-5
A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone
P. Miller (1999)
10.1016/j.bone.2013.04.024
Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes.
L. Corral-Gudino (2013)
10.1007/s00198-012-1954-5
Secular changes in Paget’s disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain
L. Corral-Gudino (2012)
10.1007/s00223-014-9904-1
Clinical Presentation of Paget’s Disease: Evaluation of a Contemporary Cohort and Systematic Review
A. Tan (2014)
10.1002/jbmr.438
A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years
I. Reid (2011)
10.1210/jc.2007-1978
Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease.
B. Matthews (2008)
10.1016/S8756-3282(99)00027-7
Paget's disease of bone: a review of 889 patients.
M. Davie (1999)
10.1148/radiology.173.2.2798865
Paget disease: MR imaging findings.
M. Roberts (1989)
10.1097/00003072-199702000-00007
The 'mouse face' appearance of the vertebrae in Paget's disease.
C. Kim (1997)
10.1007/BF00228919
Paget's disease of bone: review with emphasis on radiologic features, part II
J. Mirra (1995)
JerumsG,MelickRA,Xipell JM,ArnottR.Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget’s disease of bone
TJ Martin (1977)
10.1002/jbmr.237
Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone
D. Merlotti (2011)
10.1093/annonc/mdv307
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial
Takafumi Ueda (2015)
10.1038/ng.845
Genome-wide association identifies three new susceptibility loci for Paget's disease of bone
Omar M E Albagha (2011)
10.1056/NEJMOA044241
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
I. Reid (2005)
10.1172/JCI34257
Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.
W. Jin (2008)
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget ’ s disease of
IR Reid (2004)
10.1016/8756-3282(87)90168-2
Biochemical response to combination of disodium etidronate with calcitonin in Paget's disease.
D. ODonoghue (1987)
10.1002/JBMR.5650100318
Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease
L. Alvarez (1995)
Hearing loss in Paget's disease of bone: evidence of auditory nerve integrity.
E. Monsell (1995)
10.1007/s00223-004-0281-z
Paget’s Disease of Bone in New Zealand: Continued Decline in Disease Severity
H. Cundy (2004)
10.1016/0221-8747(81)90051-5
The role of mithramycin in the management of Paget's disease.
D. Heath (1981)
10.1097/00005131-198912000-00011
Femoral Fractures in Paget's Disease
S. Bidner (1989)
ZNF 687 mutations in severe Paget disease of bone associatedwith giant cell tumor
PL Selby
10.1359/jbmr.2004.19.4.566
Paget's Disease of Bone in The Netherlands: A Population‐Based Radiological and Biochemical Survey—The Rotterdam Study
Marelise E W Eekhoff (2004)
10.1002/jbmr.3066
Long‐Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM‐EZ Study
A. Tan (2017)
Bone scanning in evaluation of Paget's disease of bone.
P. Shirazi (1974)
10.1701/2902.29246
[GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines.]
G. P. Morgano (2018)
The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study.
S. Ralston (1987)
10.1093/RHEUMATOLOGY/KEG477
Effect of bisphosphonate treatment in patients with Paget's disease of the skull.
J. Donáth (2004)
10.1016/8756-3282(95)00282-1
Tiludronate therapy for Paget's disease of bone.
M. Mcclung (1995)
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
P. Miller (1999)
10.1016/j.ajhg.2015.12.016
ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor
G. Divisato (2016)
10.1359/jbmr.070103
Multicenter Blinded Analysis of RT‐PCR Detection Methods for Paramyxoviruses in Relation to Paget's Disease of Bone
S. Ralston (2007)
10.1016/S8756-3282(96)00224-4
Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
D. Gutteridge (1996)
10.1016/0049-0172(94)90037-X
Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions.
E. Siris (1994)
10.1002/art.1780231005
Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.
P. Meunier (1980)
10.1097/00003086-200210000-00020
Outcome of Uncemented Hip Arthroplasty Components in Patients With Paget’s Disease
J. Parvizi (2002)
10.1210/jc.2010-0597
Characterization of and risk factors for the acute-phase response after zoledronic acid.
I. Reid (2010)
10.1007/s00198-015-3095-0
Bone turnover markers in Paget’s disease of the bone: A Systematic review and meta-analysis
A. Al Nofal (2015)
10.1136/bmj.i4852
The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines
(2016)
Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clin Cases Miner Bone Metab
R Cosso (2010)
10.1136/pgmj.73.862.496
A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.
W. Fraser (1997)
10.1136/bmj.1.6168.931
Billiard-player's fingers: an unusual case of Paget's disease of bone.
L. Solomon (1979)
Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.
Roberta Cosso (2010)
10.1097/00003086-197709000-00006
Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease.
H. Wellman (1977)
10.1093/oxfordjournals.qjmed.a067432
Treatment of Paget's disease of bone with porcine calcitonin: clinical and metabolic responses.
J. Kanis (1975)
10.1016/S0002-9343(96)00227-6
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
I. Reid (1996)
10.1136/jech.37.3.226
A family study of Paget's disease of bone.
J. Sofaer (1983)
10.2106/00004623-196547030-00002
FRACTURE OF THE FEMUR IN PATIENTS WITH PAGET'S DISEASE; RESULTS OF TREATMENT IN TWENTY-THREE CASES.
J. Nicholas (1965)
10.1016/S1470-2045(13)70277-8
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
S. Chawla (2013)
10.1016/j.abb.2008.02.045
Genetics and aetiology of Pagetic disorders of bone.
M. Helfrich (2008)
10.1002/art.1780350819
Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
J. Reginster (1992)
10.1016/J.BONE.2003.10.014
The clover and heart signs in vertebral scintigraphic images are highly specific of Paget's disease of bone.
D. Rotés-Sala (2004)
10.1093/rheumatology/kew430
Adult Paget's disease of bone: a review.
Stephen Paul Tuck (2017)
10.1007/s00223-006-0184-2
Clinical Determinants of Quality of Life in Paget’s Disease of Bone
A. Langston (2006)
10.1002/JBMR.5650111103
Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with paget disease
S. Reddy (1996)
10.1359/jbmr.2005.20.3.541
Familial Aggregation of Paget's Disease of Bone
E. Siris (1991)
10.1210/jc.2014-2910
Paget's disease of bone: an endocrine society clinical practice guideline.
F. Singer (2014)
10.1016/S8756-3282(02)00876-1
Paget's disease in New Zealand: evidence for declining prevalence.
T. Doyle (2002)
Observations on serial radionuclide blood-flow studies in Paget's disease: concise communication.
R. Boudreau (1983)
10.1016/0020-1383(79)90043-3
The management of fractures in Paget's disease of bone.
D. Verinder (1979)
10.1038/71667
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
A. Hughes (2000)
in Lancashire and arsenic pesticide in cottonmill wastewater : a speculative hypothesis
LR Solomon (2002)
10.1002/14651858.CD004956.pub3
Bisphosphonates for Paget's disease of bone in adults.
L. Corral-Gudino (2017)
10.1359/jbmr.06s207
Sequestosome 1: Mutation Frequencies, Haplotypes, and Phenotypes in Familial Paget's Disease of Bone
J. Morissette (2006)
10.1302/0301-620X.72B1.2137127
Improvement in the deformity of the face in Paget's disease treated with diphosphonates.
D. Bickerstaff (1990)
10.1111/j.1445-2197.1992.tb05352.x
Outcome after fractures of the femur in Paget's disease.
C. M. Bradley (1992)
10.1007/s00223-004-0244-4
Evaluation of the Role of the SQSTM1 Gene in Sporadic Belgian Patients with Paget’s Disease
G. Beyens (2004)
10.1002/JBMR.5650020103
The effect of 1α‐hydroxyvitamin D3 on the mineralization defect in disodium etidronate‐treated paget's disease — a double‐blind randomized clinical study
S. Ralston (1987)
10.1002/JBMR.5650061115
Failure to detect paramyxovirus sequences in paget's disease of bone using the polymerase chain reaction
S. Ralston (1991)
10.1359/jbmr.2002.17.3.465
Incidence and Natural History of Paget's Disease of Bone in England and Wales
T. V. van Staa (2002)
10.1002/jbmr.64
Archaeological skeletons support a northwest European origin for Paget's disease of bone
S. Mays (2010)
10.1002/jbmr.2349
Clinical Characteristics and Evolution of Giant Cell Tumor Occurring in Paget's Disease of Bone
D. Rendina (2015)
10.1007/s00774-006-0696-x
Guidelines for diagnosis and management of Paget's disease of bone in Japan
S. Takata (2006)
10.1016/j.cell.2009.05.023
p62 at the Crossroads of Autophagy, Apoptosis, and Cancer
J. Moscat (2009)
10.2106/00004623-200304000-00017
Corrective Osteotomy for Deformity in Paget Disease
J. Parvizi (2003)
10.13107/jocr.2250-0685.594
Giant Cell Tumor Developing in Paget’s Disease of Bone: A Case Report with Review of Literature
Vivek Verma (2016)
10.1093/HMG/11.22.2735
Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease.
L. Hocking (2002)
10.1002/cncr.24121
Osteosarcoma incidence and survival rates from 1973 to 2004
L. Mirabello (2009)
10.1056/NEJM200211143472015
Osteoprotegerin deficiency and juvenile Paget's disease.
L. Hofbauer (2002)
Papilloedema in Guillain-Barré syndrome.
T. Perniola (1968)
10.1016/S8756-3282(00)00278-7
Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q.
L. Hocking (2000)
10.1210/jcem-44-1-96
Diphosphonate therapy of paget's disease of bone.
R. Canfield (1977)
10.1007/s00264-009-0853-7
Cementless total hip arthroplasty in Paget’s disease of bone: a retrospective review
J. Wegrzyn (2009)
10.1016/S0140-6736(85)90852-9
PAST PETS AND PAGET'S DISEASE
J. O'driscoll (1985)
10.1136/bmj.1.6176.1487-b
Trauma and Paget's disease of bone.
R. Hamdy (1979)
10.1007/s00223-017-0265-4
Antibody Response to Paramyxoviruses in Paget’s Disease of Bone
Micaela Rios Visconti (2017)
10.1136/bmj.328.7454.1490
Grading quality of evidence and strength of recommendations
D. Atkins (2004)
10.1302/0301-620x.52b2.252
Fractures of the femur in Paget's disease of bone. Their etiology and treatment.
M. Grundy (1970)
10.1002/JBMR.5650100421
Frequency and characteristics of familial aggregation of paget's disease of bone
A. Morales-Piga (1995)
10.1136/bmj.4.5789.719
Glucagon in the Treatment of Paget's Disease of Bone
J. Condon (1971)
10.1016/S8756-3282(02)00833-5
Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis.
J. H. Lever (2002)
10.1056/NEJM197312272892601
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
R. D. Altman (1973)
10.1016/S8756-3282(00)00343-4
Absence of measles virus and canine distemper virus transcripts in long-term bone marrow cultures from patients with Paget's disease of bone.
C. Ooi (2000)
10.1007/s11999-010-1473-7
The Role of Surgery and Adjuvants to Survival in Pagetic Osteosarcoma
P. Ruggieri (2010)
10.1359/jbmr.1999.14.5.792
Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices
H. Woitge (1999)
10.1359/jbmr.090709
Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone
A. Langston (2010)
10.1359/jbmr.2000.15.12.2315
A Negative Search for a Paramyxoviral Etiology of Paget's Disease of Bone: Molecular, Immunological, and Ultrastructural Studies in U.K. Patients
M. Helfrich (2000)
10.1359/jbmr.060704
Epidemiology of Paget's Disease in Europe: The Prevalence Is Decreasing
G. Poór (2006)



This paper is referenced by
10.1002/jbmr.3964
The loss of Profilin 1 causes early-onset Paget's disease of bone.
Federica Scotto di Carlo (2020)
10.1016/j.bone.2019.04.023
Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone.
Núria Guañabens (2019)
10.3389/fcell.2020.00399
Paget’s Disease and Secondary Hyperparathyroidism: Is Healing Possible?
Vincenzo Antonio Panuccio (2020)
10.1007/s00198-019-05259-1
Management of Paget’s disease of bone
I R Reid (2019)
10.12688/f1000research.19676.1
Recent advances in understanding and managing Paget’s disease
Ian R. Reid (2019)
10.11005/jbm.2020.27.1.71
Paget's Disease of Bone Affecting Peripheral Limb: Difficulties in Diagnosis: A Case Report
Jun-Ku Lee (2020)
10.1016/j.bone.2020.115465
Bisphosphonates in the management of Paget's disease.
Stuart H Ralston (2020)
10.1016/j.jocd.2019.09.006
Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases.
E Michael Lewiecki (2019)
10.1016/j.wneu.2019.12.099
Management of hydrocephalus in Paget's disease of bone: systematic review and illustrative case.
Abdelsimar T Omar (2019)
10.1111/nyas.14332
Bisphosphonates and atrial fibrillation: revisiting the controversy.
Ibrahim T. Fazmin (2020)
10.1002/OA.2807
Paget's disease of bone in two medieval skeletons from Poulton Chapel, Cheshire, UK
Carla L. Burrell (2019)
10.1136/bmjopen-2019-030689
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
O. Cronin (2019)
10.1002/jbmr.3874
Reply to Clinical Guidelines on Paget's Disease
B. Langdahl (2019)
10.1002/jbmr.3709
A Clinical Guideline on Paget’s Disease of bone—A Guideline or a Review?
B. Langdahl (2019)
10.1159/000507663
Quantitative Bone Single Photon Emission Computed Tomography/Computed Tomography for Evaluating Response to Bisphosphonate Treatment in Patients with Paget's Disease of Bone
K. Kitajima (2020)
10.1002/jbmr.4007
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort
O. Cronin (2020)
10.1007/s11154-020-09544-x
Clinical features, diagnosis and treatment of Paget’s disease of bone in mainland China: A systematic review
Q. Wang (2020)
10.1016/j.bone.2019.115044
Familial Paget's disease of bone: Long-term follow-up of unaffected relatives with and without Sequestosome 1 mutations.
J. J. M. Peeters (2019)
10.1007/s00223-019-00556-7
Focal and Osteosclerotic Bone Diseases
S. Ralston (2019)
10.1002/jbmr.3873
Clinical Guidelines on Paget's Disease of Bone
S. Ralston (2019)
Semantic Scholar Logo Some data provided by SemanticScholar